Genmab A/S (GMAB)
NASDAQ·Healthcare·Biotechnology
$53.44
-0.19%
Mkt Cap $16.79B
Analyst Ratings
No recent rating data.
Price Target (22 analysts)
$38.25
Range $32.00 – $43.00
Implied Upside
-28.4%
Consensus $38.25 vs current $53.44
NASDAQ·Healthcare·Biotechnology
$53.44
-0.19%
Mkt Cap $16.79B
No recent rating data.
Price Target (22 analysts)
$38.25
Range $32.00 – $43.00
-28.4%
Consensus $38.25 vs current $53.44